BPC-157 and TB-500 are two of the most searched research peptides, and they are almost always mentioned together. Their research overlaps in tendon, wound and blood-vessel models, but the molecules themselves have nothing in common: BPC-157 is a short synthetic peptide taken from a gastric juice protein, while TB-500 is based on thymosin β4, an actin-binding protein found inside nearly every cell. This guide compares them side by side and links to the full research overview for each.
All compounds discussed are sold for laboratory research use only. This page summarizes published research and is not guidance for human or veterinary use.
At a glance
| BPC-157 | TB-500 (thymosin β4) | |
|---|---|---|
| Origin | Partial sequence of a protein described in human gastric juice | Thymosin β4, first purified from calf thymus extract and later found in most cell types |
| Size | 15 residues, 1419.5 g/mol | 43 residues, 4963 g/mol (full-length, N-terminally acetylated) |
| Sequence features | Linear, four prolines including a run of three near the N-terminus; net negative charge | Acetylated N-terminal serine; conserved actin-binding motif starting at residue 17 |
| Best-documented biology | Downstream signaling in fibroblasts and endothelial cells (FAK-paxillin, VEGFR2) | Binds and sequesters actin monomers (G-actin) in a 1:1 complex |
| Identified receptor | None | No dedicated cell-surface receptor confirmed |
| Main research areas | Tendon and fibroblast biology, angiogenesis, wound models, gut-brain axis | Endothelial migration, cardiac and dermal injury models, tendon repair, anti-doping analytics |
| Who studied it most | Predrag Sikiric’s group, University of Zagreb | Several groups; first characterized by Allan Goldstein’s laboratory |
| Regulatory status | Not FDA approved; WADA Prohibited List S0 since 2022 | Not FDA approved; WADA S2 (thymosin β4 and its derivatives) |
| Full overview | BPC-157 research | TB-500 research |
Two unrelated molecules, overlapping research
BPC-157 and TB-500 come from completely different sources and share no sequence. What links them is the questions researchers ask: both have been studied in tendon, wound and vascular models, and both come up in work on how cells migrate. That overlap is why they are so often compared, and why one exploratory animal study has tested them together.
The key difference is how much is known about each mechanism. TB-500’s core biochemistry, binding actin inside the cell, is well established. BPC-157 has no known receptor, so its mechanism is described through downstream signaling changes.
BPC-157: a short synthetic peptide
BPC-157 is a 15-residue sequence taken from a protein fraction the Sikiric group reported isolating from human gastric juice. It is made by solid-phase synthesis and was described in early papers as stable in gastric juice, which set it apart from many peptides.
In cultured rat Achilles tendon fibroblasts, BPC-157 was associated with increased phosphorylation of focal adhesion kinase (FAK) and paxillin, and with greater cell spreading and migration (Chang et al., 2011). In human endothelial cells it was linked to activation of VEGFR2 and downstream Akt and eNOS signaling, connected to vessel formation in a rat hindlimb ischemia model (Hsieh et al., 2017).
Read the full BPC-157 research overview or view BPC-157.
TB-500: built on thymosin β4
Thymosin β4 is a 43-residue protein whose best-established job is holding actin monomers in reserve, so cells can rebuild their cytoskeleton quickly. Safer and colleagues showed it was the same molecule as a platelet actin-sequestering factor (Safer et al., 1991). Because cell movement depends on fast actin turnover, later studies found that added Tβ4 increased directional migration of human endothelial cells (Malinda et al., 1997).
The name “TB-500” causes confusion. In doping-control literature it refers to a short synthetic fragment of the actin-binding region. Elsewhere it is a label for full-length thymosin β4. The TB-500 Rogue Compounds sells is the full 43-residue peptide, and the batch COA records what was found in the vial.
Read the full TB-500 research overview or view TB-500.
Where their research overlaps
- Tendon: BPC-157 has tendon fibroblast and explant studies (Chang et al., 2011). Thymosin β4 has been studied in tendon repair, and a 2026 rat Achilles tendon study compared the two peptides alone and together (Biçer et al., 2026).
- Blood vessels: Both have been studied in endothelial cell assays and vessel-formation models (Hsieh et al., 2017; Malinda et al., 1997).
- Wound models: Both have been examined in rodent wound models, with readouts such as re-epithelialization and collagen deposition.
- Cell migration: Migration assays are central to both literatures, through focal adhesion signaling for BPC-157 and actin dynamics for thymosin β4.
Studied together
The 2026 rat Achilles tendon study is the only published work found that tested BPC-157 and TB-500 in combination, using histopathology and biomechanical load testing. The authors described their results as exploratory (Biçer et al., 2026). One rodent study is a starting point, not an established finding. For labs running both peptides in the same model, Rogue also offers a BPC-157 + TB-500 blend made as a single lot with one COA. See the blend research overview.
How researchers choose between them
- Studying actin and the cytoskeleton: TB-500 is the relevant tool, because actin sequestration is its best-established function.
- Studying focal adhesion or VEGFR2 signaling: BPC-157 is the peptide with published data on these pathways in fibroblasts and endothelial cells.
- Comparing two repair-model peptides in one system: running both, alone and combined, follows the design of the 2026 tendon study.
What the research does not show
Both literatures come almost entirely from cell culture and animal models. A 2025 systematic review of BPC-157 in orthopaedic and sports medicine found the evidence almost entirely preclinical, with no clinical safety data (Vasireddi et al., 2025). A large share of BPC-157 papers come from one research group. For TB-500, studies use different molecules under the same name, so results for a fragment cannot be assumed for the full-length peptide. Neither compound has an identified receptor, and neither is approved for any medical use. None of these findings establishes any effect in people or describes the research material sold here.
Verify what you’re working with
Because “TB-500” can mean either a 7-residue fragment or the full 43-residue protein, identity testing matters more here than for most peptides. Every Rogue batch is tested by an independent, ISO 17025 accredited U.S. lab, and the QR code on each vial opens that batch’s report on the lab’s own website. See how to read a peptide COA or browse the COA Library.
View BPC-157 on Rogue Compounds
References
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966
- Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398
- Malinda KM, et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. PMID 9194528
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949
Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.
Compounds researchers often order together, 5% off as a set. Every vial ships with its batch COA.
TB-500 + GHK-CuFrom $104.50 
BPC-157 + KPVFrom $117.80 
TB-500 + THYMOSIN ALPHA-1From $114.00